Trials / Recruiting
RecruitingNCT05534438
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.
Conditions
- Oligometastatic Breast Carcinoma
- Breast Cancer
- Metastatic Breast Cancer
- Metastatic Breast Carcinoma
- ER+ Breast Cancer
- HER2+ Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic body radiotherapy | SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays) |
Timeline
- Start date
- 2022-09-06
- Primary completion
- 2026-09-06
- Completion
- 2026-09-06
- First posted
- 2022-09-09
- Last updated
- 2026-04-16
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05534438. Inclusion in this directory is not an endorsement.